Track topics on Twitter Track topics that are important to you
ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid diseases. ProteoTechâs lead small molecule drug, Systebrylâ¢ (PTI-110), will soon be entering a Phase 1/2 proof-of-concept clinical trial in patients with AL (immunoglobulin light chain) amyloidosis (a recognized rare or "orphan" disease). Other products in the ProteoTech pipeline include a small molecule drug that is designed to inhibit and stimulate the reduction of insoluble alpha-synuclein aggregate accumulation (involved in Multiple System Atrophy and Parkinsonâs disease), small molecule drugs intended to inhibit and reduce tau protein and/or beta-amyloid protein aggregates (involved in Progressive Supranuclear Palsy and Alzheimerâs disease), and small molecule drugs intended to inhibit and reduce beta-2 microglobulin protein aggregates (involved in dialysis-related amyloidosis). For further information, please visit www.proteotech.com, email firstname.lastname@example.org, or telephone +1-425-823-0400.
ProteoTech is a privately-held, drug development company that utilizes its amyloid expertise to discover and develop new drugs for treating misfolded protein disorders and amyloid...
Company Description: ProteoTech Inc. is a world leader in research and development of new therapeutics derived from proteoglycan and amyloid technologies for the treatment of major human diseases. Pro...
We have published hundreds of ProteoTech Inc. news stories on BioPortfolio along with dozens of ProteoTech Inc. Clinical Trials and PubMed Articles about ProteoTech Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ProteoTech Inc. Companies in our database. You can also find out about relevant ProteoTech Inc. Drugs and Medications on this site too.